Navigation Links
PharmAthene to Provide Update on SparVax(TM) Contract Modification Suspension During Year-End 2009 Financial and Operational Results Conference Call on Tuesday March 23, 2010
Date:3/22/2010

2';s.tl(this,'o','ExternalLink');" target='_blank' href="http://www.pharmathene.com/">www.pharmathene.com.  A link to the webcast may be found under the Investor Relations section of the website.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

  • SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine
  • Third generation rPA anthrax vaccine
  • Valortim(R) - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
  • Protexia(R) - a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents

For more information about PharmAthene, please visit

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010
2. PharmAthene to Present at the 2010 Roth Capital Markets Growth Stock Conference on Monday, March 15, 2010
3. PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine
4. PharmAthene Appoints Jeffrey W. Runge, M.D. to the Companys Board of Directors
5. PharmAthene Announces Updated Time for Conference Call to Review BARDA rPA Decision
6. PharmAthene Reports Third Quarter 2009 Financial and Operational Results
7. PharmAthene Executives Featured in Anthrax Pathogen Training Video for U.S. Department of Homeland Security
8. PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference
9. PharmAthene to Present at the Rodman and Renshaw Annual Global Investment Conference September 10, 2009
10. PharmAthene Reports Second Quarter 2009 Financial and Operational Results
11. PharmAthene to Host Second Quarter 2009 Conference Call and Webcast on Thursday, August 13, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... 2014 Today, Nerium International, a leader ... of its “Reflect Your Youth” contest, an effort launched ... a difference in their skin since using Nerium’s product ... on life as a result of their newfound confidence. ... effort by Nerium International to inspire conversations focused on ...
(Date:10/25/2014)... , October 24, 2014 Oramed ... pharmaceutical company focused on the development of oral drug ... Nadav Kidron will present at FireRock Capital,s Micro-Cap ... Annual Micro-Cap Conference ,Date: Tuesday, October 28, 2014 ,Time: ... New York City , ...
(Date:10/25/2014)... 24, 2014 Research and Markets ... by Product , Research Area & by End User ... offering. In this report, the global ... research areas, and end users. The product segments of ... instruments & consumables, kits, and reagents. The subsegments of ...
(Date:10/22/2014)... BOSTON , Oct. 22, 2014  Actavis plc ... pharmaceutical company, and Rhythm, a biopharmaceutical company, today announced ... acquire Rhythm,s wholly owned subsidiary, Rhythm Health, Inc., which ... the treatment of diabetic gastroparesis and other GI functional ... Phase 2 trial of relamorelin for the treatment of ...
Breaking Biology Technology:Nerium International™ Inspires Conversation About the Journey of Aging with “Reflect Your Youth” Contest 2Oramed to Present at the FireRock Annual Micro-Cap Conference 2Oramed to Present at the FireRock Annual Micro-Cap Conference 3Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5
... launch of a new series of web-based training programs for professionals ... courses are one hour in duration and designed specifically for the ... ... Salt Lake City, Utah (PRWEB) December 11, 2008 -- ...
... Schering-Plough Corporation (NYSE: SGP ) today declared a quarterly ... made on Feb. 27, 2009, to shareholders of record at the ... 30, 2008, there were 1,626,234,628 common shares outstanding. , ... declared a quarterly dividend of $3.75 per share on the 2007 ...
... of Hematology Annual Meeting , , ... ACEL ) today announced that American Society of Hematology ... Abstract 4205 & 2008 112: Abstract 4010) report that ONCONASE ... leukemia (CLL) and acute myeloblastic leukemia (AML) cells alone as ...
Cached Biology Technology:McCulley/Cuppan Announced Today The Launch Of A New Series Of Web-Based Training Programs For Professionals In The Biopharmaceutical And Life Science Industries 2McCulley/Cuppan Announced Today The Launch Of A New Series Of Web-Based Training Programs For Professionals In The Biopharmaceutical And Life Science Industries 3Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 2Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 3Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 4Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells 5
(Date:10/22/2014)... (NASDAQ: AWRE ), a leading supplier of biometrics ... quarter ended September 30, 2014. Revenue for the ... 40% compared to $4.3 million in the same quarter last ... $4.1 million compared to $1.0 million in the third quarter ... period was primarily due to: i) a $1.0 million increase ...
(Date:10/18/2014)... stress and stress-related psychiatric disorders are associated ... the molecular mechanisms underlying this relation are ... the development of targeted preventive strategies and ... diseases. This work is presented at the ... Now an international group of researchers from ...
(Date:10/18/2014)... suspected genetic conditions, a certain type of exome sequencing ... than traditional molecular diagnostic methods, according to a study ... released to coincide with the American Society of Human ... protein­coding region of the genome (the complete set of ... organism), has been rapidly applied in research settings and ...
Breaking Biology News(10 mins):Aware, Inc. Reports Third Quarter 2014 Financial Results 2Aware, Inc. Reports Third Quarter 2014 Financial Results 3Aware, Inc. Reports Third Quarter 2014 Financial Results 4Aware, Inc. Reports Third Quarter 2014 Financial Results 5Aware, Inc. Reports Third Quarter 2014 Financial Results 6Aware, Inc. Reports Third Quarter 2014 Financial Results 7Researchers find why depression and aging linked to increased disease risk 2Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3
... CAFebruary 23, 2014The power of regenerative medicine now allows ... resemble heart cells, pancreas cells and even neurons. However, ... crucial prerequisite for life-saving therapieshas proven far more difficult. ... University of California, San Francisco (UCSF), have made an ...
... New Rochelle, NY, February 20, 2014A new era of manufacturing ... manufacturing technologies are set to usher in the next generation ... of this groundbreaking new technology, Mary Ann Liebert, Inc., publishers ... new peer-reviewed journal 3D Printing and Additive Manufacturing ...
... [Brown University] Here are two facts that make ... ecology research, and they are very sensitive to temperature. ... a bellwether community of two barnacle species in Chile ... these two species if they experimentally changed temperature. In ...
Cached Biology News:Scientists transform skin cells into functioning liver cells 2Scientists transform skin cells into functioning liver cells 33-D Printing and Additive Manufacturing: Preview issue of groundbreaking peer-reviewed journal now available 2Temperature and ecology: Rival Chilean barnacles keep competition cool 2Temperature and ecology: Rival Chilean barnacles keep competition cool 3
A compact, high-speed single tube reader unit designed for benchtop 2D barcode reading. The unit can be used with all of ABgene's 2D barcoded tubes, including the 2ml CryoCode tube....
... PCR carry-over contamination, which prevents false ... products from previous PCR amplifications without ... improves amplification ,Optimized for use with ... instrument systems , The GeneAmp PCR ...
... a-Amylase is an enzyme that catalyzes ... of maltose, maltotriose, and dextrins. The,level ... the human body is of,clinical significance ... including,pancreatitis and diabetes; plant and microbial ...
... Labsystems Wellmix is a high-quality four-place microplate ... The shaking speed is adjustable from 100 ... speed and a small orbit ensure effective ... time is quick and easy to set ...
Biology Products: